TEVOGEN INC Financials
This page shows TEVOGEN INC (TVGN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Tevogen Bio’s dominant operating mechanic is an externally funded cash burn, with little sign that spending is building fixed assets.
In FY2025, free cash flow of-$12.4M was nearly the same as operating cash flow of-$12.3M because capital spending was only$64K ; matched against$11.7M of financing inflow, that means new capital is mainly covering operating use of cash rather than creating a larger asset base. The same pattern was visible in FY2024, so this looks like a recurring funding structure, not a one-off reset.
The balance sheet changed shape sharply after FY2023: total liabilities fell from
FY2025 spending was not primarily a facilities build-out: SG&A at
Financial Health Signals
TEVOGEN INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
TEVOGEN INC recorded an outflow of $12.4M in free cash flow in fiscal year 2025, representing a cash shortfall after capex.
TEVOGEN INC held $0 in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
TEVOGEN INC invested $11.1M in research and development in fiscal year 2025.
TEVOGEN INC invested $64K in capex in fiscal year 2025, funding long-term assets and infrastructure.
Not reported for fiscal year 2025.
TVGN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| R&D Expenses | N/A | $11.1M | N/A | $4.4M | N/A |
| SG&A Expenses | N/A | $15.0M | N/A | $4.4M+365.8% | $953K |
| Operating Income | N/A | N/A | N/A | -$8.8M | N/A |
| Interest Expense | N/A | -$196K-206.3% | $184K-84.7% | $1.2M | N/A |
| Income Tax | N/A | $5K+171.4% | $2K | N/A | N/A |
| Net Income | N/A | N/A | -$13.7M | N/A | $4.4M |
| EPS (Diluted) | — | -$8.08 | -$3.50-43.4% | -$2.44 | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TVGN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Total Assets | $4.4M+26.6% | $3.5M-37.1% | $5.5M-98.5% | $357.1M |
| Current Assets | $1.5M-34.8% | $2.4M+37.0% | $1.7M+528.0% | $274K |
| Cash & Equivalents | $0 | $0 | $0-100.0% | $129K |
| Total Liabilities | $12.6M+24.5% | $10.1M-89.9% | $99.9M-74.4% | $391.1M |
| Current Liabilities | $7.1M-21.8% | $9.0M-89.4% | $85.5M+24291.1% | $350K |
| Total Equity | -$8.2M-23.4% | -$6.7M+92.9% | -$94.4M-178.1% | -$34.0M |
| Retained Earnings | -$139.7M-23.2% | -$113.4M-13.8% | -$99.7M-574.1% | -$14.8M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
TVGN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$11.6M | -$12.3M-2.7% | -$12.0M-46.8% | -$8.2M-3693.6% | -$215K |
| Capital Expenditures | N/A | $64K | N/A | $133K | N/A |
| Free Cash Flow | N/A | -$12.4M | N/A | -$8.3M | N/A |
| Investing Cash Flow | N/A | -$64K | N/A | -$133K | N/A |
| Financing Cash Flow | $12.0M | $11.7M-4.6% | $12.2M+215.8% | $3.9M | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TVGN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Return on Assets | N/A | -396.6% | N/A | 1.2% |
| Current Ratio | 0.220.0x | 0.26+0.2x | 0.02-0.8x | 0.78 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, FCF Margin.
Note: Shareholder equity is negative (-$8.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.22), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where TEVOGEN INC Ranks
Frequently Asked Questions
What is TEVOGEN INC's free cash flow?
TEVOGEN INC (TVGN) recorded an outflow of $12.4M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is TEVOGEN INC's operating cash flow?
TEVOGEN INC (TVGN) recorded an outflow of $12.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are TEVOGEN INC's total assets?
TEVOGEN INC (TVGN) had $4.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are TEVOGEN INC's capital expenditures?
TEVOGEN INC (TVGN) invested $64K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does TEVOGEN INC spend on research and development?
TEVOGEN INC (TVGN) invested $11.1M in research and development during fiscal year 2025.
What is TEVOGEN INC's current ratio?
TEVOGEN INC (TVGN) had a current ratio of 0.22 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
How does TEVOGEN INC's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, TEVOGEN INC (TVGN) held $0 in cash, cash equivalents and investments, and reported an operating cash outflow of $12.3M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is TEVOGEN INC's debt-to-equity ratio negative or not reported?
TEVOGEN INC (TVGN) has negative shareholder equity of -$8.2M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.